nChroma (formerly Chroma Medicine)

nChroma Bio

The company develops liver-targeted epigenetic editing therapies and non-viral delivery systems to treat patients with chronic hepatitis B and hepatitis D.

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

In vivo cell reprogramming

Enoda Bio develops genetic medicines that reprogram patient cells inside the body to treat chronic diseases for healthcare providers and pharmaceutical partners.

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.

Epicrispr

This company develops epigenomic therapies to control gene expression in patients with complex diseases.

EdiTy Therapeutics

This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.

Bluejay Therapeutics

The company develops monoclonal antibody therapies and small molecule drugs to treat patients with chronic hepatitis B, hepatitis D and other liver diseases.